JP2016538328A - Pde4阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 - Google Patents
Pde4阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 Download PDFInfo
- Publication number
- JP2016538328A JP2016538328A JP2016545257A JP2016545257A JP2016538328A JP 2016538328 A JP2016538328 A JP 2016538328A JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016538328 A JP2016538328 A JP 2016538328A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- nutritional supplement
- forskolin
- carnitine
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title description 18
- 229960003638 dopamine Drugs 0.000 title description 9
- 230000027928 long-term synaptic potentiation Effects 0.000 title description 9
- 230000005764 inhibitory process Effects 0.000 title description 6
- 235000013376 functional food Nutrition 0.000 title description 3
- 230000004060 metabolic process Effects 0.000 title description 3
- 230000006872 improvement Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 title description 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims abstract description 181
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims abstract description 91
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims abstract description 91
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 80
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 75
- 230000001965 increasing effect Effects 0.000 claims abstract description 72
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 65
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 58
- 230000001777 nootropic effect Effects 0.000 claims abstract description 57
- 239000000284 extract Substances 0.000 claims abstract description 49
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 49
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 48
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 40
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 40
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 40
- 244000019459 Cynara cardunculus Species 0.000 claims abstract description 38
- 235000019106 Cynara scolymus Nutrition 0.000 claims abstract description 38
- 235000016520 artichoke thistle Nutrition 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 36
- 230000003920 cognitive function Effects 0.000 claims abstract description 30
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 29
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930003935 flavonoid Natural products 0.000 claims abstract description 25
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 25
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 25
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000009498 luteolin Nutrition 0.000 claims abstract description 20
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 16
- 229930002697 labdane diterpene Natural products 0.000 claims abstract description 13
- 239000000419 plant extract Substances 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 93
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 37
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 30
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 30
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 21
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 21
- 235000019100 piperine Nutrition 0.000 claims description 21
- 229940075559 piperine Drugs 0.000 claims description 21
- 229930182470 glycoside Natural products 0.000 claims description 19
- 229960005190 phenylalanine Drugs 0.000 claims description 19
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 18
- 150000002338 glycosides Chemical class 0.000 claims description 17
- HDNHBCSWFYFPAN-IRXDYDNUSA-N Mesembrenone Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(C=CC(=O)C2)[C@H]2N(C)CC1 HDNHBCSWFYFPAN-IRXDYDNUSA-N 0.000 claims description 15
- HDNHBCSWFYFPAN-UHFFFAOYSA-N mesembrenone Natural products C1=C(OC)C(OC)=CC=C1C1(C=CC(=O)C2)C2N(C)CC1 HDNHBCSWFYFPAN-UHFFFAOYSA-N 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 12
- -1 biocanin A Chemical compound 0.000 claims description 12
- 235000021283 resveratrol Nutrition 0.000 claims description 12
- 229940016667 resveratrol Drugs 0.000 claims description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 11
- 229930013930 alkaloid Natural products 0.000 claims description 11
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 10
- 235000021508 Coleus Nutrition 0.000 claims description 10
- 244000061182 Coleus blumei Species 0.000 claims description 10
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 10
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 10
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 10
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 10
- 229940025878 hesperidin Drugs 0.000 claims description 10
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 10
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 10
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 9
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 9
- 229940045109 genistein Drugs 0.000 claims description 9
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 9
- 235000006539 genistein Nutrition 0.000 claims description 9
- 229960001285 quercetin Drugs 0.000 claims description 9
- 235000005875 quercetin Nutrition 0.000 claims description 9
- 150000003436 stilbenoids Chemical class 0.000 claims description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 7
- 235000005273 Canna coccinea Nutrition 0.000 claims description 5
- 240000008555 Canna flaccida Species 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000002664 nootropic agent Substances 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 229930004069 diterpene Natural products 0.000 claims 1
- 150000004141 diterpene derivatives Chemical class 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract description 5
- 230000015654 memory Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 12
- 229950005741 rolipram Drugs 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 7
- 230000006403 short-term memory Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000012440 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 230000008450 motivation Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000291564 Allium cepa Species 0.000 description 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 3
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 2
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 108050008598 Phosphoesterases Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 240000002913 Trifolium pratense Species 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000012093 association test Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229950009125 cynarine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WDJJFDJQYGLZPA-CGPDBNODSA-N (3R,4aS,5S,6S,6aS,10S,10aS,10bR)-3-ethenyl-5,6,10-trihydroxy-3,4a,7,7,10a-pentamethyl-2,5,6,6a,8,9,10,10b-octahydrobenzo[f]chromen-1-one Chemical compound O1[C@@](C)(C=C)CC(=O)[C@@H]2[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](O)[C@]21C WDJJFDJQYGLZPA-CGPDBNODSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical compound C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000003198 Cynara Nutrition 0.000 description 1
- 241000208947 Cynara Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 description 1
- 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 description 1
- 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
- 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WPDITXOBNLYZHH-UHFFFAOYSA-N desacetylforskolin Natural products O1C(C)(C=C)CC(=O)C2(O)C3(C)C(O)CCC(C)(C)C3C(O)C(O)C21C WPDITXOBNLYZHH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 description 1
- 229950009329 etazolate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003128 phytoestrogenic effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003244 quercetin derivatives Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000013114 radial arm maze test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本願は、2013年9月27日に出願された米国仮特許出願第61/883,433号、2014年9月6日に出願された米国仮特許出願第62/046,953号、および2014年9月7日に出願された米国仮特許出願第62/047,055号の利益を主張し、その開示内容の全体は、全ての目的のために、参照により本願明細書に包含される。
本発明は、栄養補給剤およびその使用方法に関する。
1または複数の植物抽出物の形態で向知性作用を有する組み合わせ剤に加えられることができる。例えば、向知性作用を有する組み合わせ剤は、PDE4阻害剤源のルテオリンとしてアーティチョーク抽出物を含むことができ、フォルスコリン源としてコレウスフォルスコリ抽出物を含むことができる。上述のように、PDE4阻害剤源として用いられることができる植物抽出物は、これらに限られる訳ではないが、玉ねぎ、柑橘植物、ムラサキツメクサ、および大豆、またはこれらの任意の組み合わせを含む。
200mgのアセチル−L−カルニチンと、
1mgのフォルスコリンと、
5%シナリンに規格化された、225mgのアーティチョーク抽出物と、
125mgのL−フェニルアラニンと、
2.5mgのビタミンB6と、
を含む。
200mgのアセチル−L−カルニチン、
1mgのフォルスコリン、
5%シナリンに規格化された、225mgのアーティチョーク抽出物、
または、
1mgのフォルスコリン、
5%シナリンに規格化された、225mgのアーティチョーク抽出物、
125mgのL−フェニルアラニン、
を含む。
約180mg〜約440mg、約180mg〜約660mg、または約180mg〜約880mgのアセチル−L−カルニチン、
約112.5mg〜約275mg、約112.5mg〜約412.5mg、または約112.5mg〜約550mgのL−フェニルアラニン、および、
約2.25mg〜約5.5mg、約2.25mg〜約8.25mg、または約2.25mg〜約11mgのビタミンB6。
アーティチョーク抽出物およびフォルスコリン
本発明者は、5%シナリンに規格化された、900mgのアーティチョーク抽出物(イリノイ州ブルーミングデールのNow Foods)と、1%フォルスコリンに規格化され、3.85mgのフォルスコリンを生じる、385mgのコレウスフォルスコリ根(ユタ州パークシティのNeutraceutical)とを摂取した。該組み合わせ剤は、毎朝1回投与された。前記組み合わせ剤を摂取後、本発明者は、基準と比べて、空間探索および文法的推論テストの結果が良好であった。本発明者は意欲の増加を感じ、長時間学習することができた。主観的ではあるが、彼はまた、学習された材料を良好に記憶した。本発明者は、昼に極度の疲労を感じ、一対の項目(対象とその位置)を記憶する対連合学習テストである「Paired Associates」(カナダオンタリオ州のCambridge Brain Sciences)によって測定された短期記憶は、僅かに負の影響を受けた。
アーティチョーク抽出物、フォルスコリンおよびL−フェニルアラニン
本発明者は、実施例1のようにアーティチョーク抽出物とフォルスコリンとを摂取し、さらに、L−フェニルアラニン(イリノイ州ブルーミングデールのNow Foods)を1500mgまで摂取した。該組み合わせ剤は、毎朝1回投与された。前記組み合わせ剤を摂取後、本発明者は、基準と比べて、空間探索および文法的推論テストの結果が良好であり、意欲の増加を感じ、長時間学習することができ、主観的ではあるが、学習された材料を良好に記憶した。単にアーティチョーク抽出物とフォルスコリンとを含む組み合わせ剤と比べて、本発明者が昼に感じる疲労は少なかった。対連合学習テストである「Paired Associates」(カナダオンタリオ州のCambridge Brain Sciences)によって測定された短期記憶は、僅かに負の影響を受けた。
アーティチョーク抽出物、フォルスコリン、L−フェニルアラニンおよびビタミンB6
本発明者は、実施例2のように、アーティチョーク抽出物と、フォルスコリンと、L−フェニルアラニンとを摂取し、さらに、ビタミンB複合体(ユタ州パークシティのNeutraceutical)の一部としての5mgのビタミンB6を摂取した。該組み合わせ剤は、毎朝1回投与された。前記組み合わせ剤を摂取後、本発明者は、基準と比べて、空間探索および文法的推論テストの結果が良好であり、意欲の増加を感じ、長時間学習することができ、主観的ではあるが、学習された材料を良好に記憶した。発明者が昼に感じる疲労は少なく、積み重ね(Stack)の効果は、前記組み合わせ剤を摂取した数日間に亘って、減じなかった。対連合学習テストである「Paired Associates」(カナダオンタリオ州のCambridge Brain Sciences)によって測定された短期記憶は、僅かに負の影響を受けた。
アーティチョーク抽出物、フォルスコリン、L−フェニルアラニン、ビタミンB6およびL−カルニチン
本発明者は、実施例3のように、アーティチョーク抽出物と、フォルスコリンと、L−フェニルアラニンと、ビタミンB6とを摂取し、さらに、750mgのアセチル−L−カルニチン(ノースカロライナ州バーリングトンのPrimaforce)を摂取した。該組み合わせ剤は、毎朝1回投与された。前記組み合わせ剤を摂取後、本発明者は、基準と比べて、空間探索および文法的推論テストの結果が良好であり、意欲の増加を感じ、長時間学習することができ、主観的ではあるが、学習された材料を良好に記憶した。本発明者は昼に疲労を感じなかった。フォルスコリンに対するアセチル−L−カルニチンの量は、前記組み合わせ剤を摂取後、本発明者の対連合スコアがこれ以上低下しなくなるまで増加された。
この実施例は、被検体による証明書に基づく。被検体は、集中力および記憶力に問題がある女性であった。栄養補給剤は、カプセル形態であり、カプセルは、5%シナリンに規格化された、300mgのアーティチョーク抽出物、約4/3mgのフォルスコリン、167mgのL−フェニルアラニン、5/3mgのビタミンB6、および250mgのアセチル−L−カルニチンを含んでいた。さらに、担体としての、セルロース、植物性ステアリン酸、およびシリカが含まれていた。栄養補給剤を摂取後、被検体は、関心、気力および記憶力の増加を報告した。
この実施例は、男性の被検体による証明書に基づく。栄養補給剤は、カプセル形態であり、カプセルは、5%シナリンに規格化された、300mgのアーティチョーク抽出物、約4/3mgのフォルスコリン、167mgのL−フェニルアラニン、5/3mgのビタミンB6、および250mgのアセチル−L−カルニチンを含んでいた。さらに、担体としての、セルロース、植物性ステアリン酸、およびシリカが含まれていた。栄養補給剤を摂取後、被検体は、関心および心理的視野の増加を報告した。
この実施例は、男性の被検体による証明書に基づく。栄養補給剤は、カプセル形態であり、カプセルは、5%シナリンに規格化された、300mgのアーティチョーク抽出物、約4/3mgのフォルスコリン、167mgのL−フェニルアラニン、5/3mgのビタミンB6、および250mgのアセチル−L−カルニチンを含んでいた。さらに、担体としての、セルロース、植物性のステアリン酸、およびシリカが含まれていた。栄養補給剤を摂取後、被検体は、関心および集中力の増加を報告した。
本発明者は、25mgのカンナ抽出物(カリフォルニア州ロスアンゼルスのOrganic African Red Tea ImportsのZembrin(登録商標))、1500mgのL−フェニルアラニン、および4mgのフォルスコリン(カリフォルニア州ヴェンチュラのBetter Body Sports LLC)を摂取した。この組み合わせ剤は、毎朝1回投与された。前記組み合わせ剤を摂取後、本発明者は、「Polygons」および「Odd One Out」テスト(カナダオンタリオ州のCambridge Brain Sciences)において、より良好なスコアを得た。学習は、より容易になり、より楽しくなった。
以下の刊行物は、参照により本明細書に包含される。
1.Rutten K,Van donkelaar EL,Ferrington L,et al.Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.Neuopsychopharmacology.2009;34(8):1914−25.PMID 19262466.
2.Egawa T,Mishima K,Matsumoto Y,Iwasaki K,Iwasaki K,Fujiwara M.Rolipram and its optical isomers,phosphodiesterase 4 inhibitors,attenuated the scopolamine−induced impairments of learning and memory in rats.Jpn J Phamacol.1997;75(3):275−81.PMID 9434259.
3.Zhang HT,O’donnell JM.Effects of rolipram on scopolamine−induced impairment of working and reference memory in the radial−arm maze tests in rats.Phychopharmaclogy(Berl).2000;150(3):311−6.PMID 10923759.
4.Zhang HT,Crissman AM,Dorairaj NR,Chandler LJ,O’donnell JM.Inhibition of cycle AMP phosphodiesterase(PDE4) reverses memory deficits associated with NMDA receptor antagonism.Neuropsychopharmacology.202;23(2):198−204.PMID 10882846.
5.Zhang HT,Huang Y,Suvarna NU,et al.Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial−arm maze and inhibitory avoidance tests in rats.Phychopharmacology(Berl).2005;179(3):613−9.PMID 15672274.
6.Mclean JH,Smith A,Rogers S,Clarke K,Darby−king A,Harley CW.A phosphodiesterase inhibitor,cilomilast,enhances cAMP activity to restore conditioned odor preference memory after serotonergic depletion in the neonate rat.Neurobiol Learn Mem.2009;92(1):63−9.PMID 19233302.
7.Wang C,Yang XM,Zhuo YY,et al.The phosphodiesterase−4 inhibitor rolipram reverses Aβ−induced cognitive impairment and neuroinflammatory and apoptic respnses in rats.Int J Neurophychopharmacol.2012;15(6):749−66.PMID 21733236.
8.Rose GM,Hopper A,De vivo M,Tehim A.Phosphodiesterase inhibitors for cognitive enhancement.Curr Pharm Des.2005;11(26):3329−34.PMID 16250839.
9.Drott J,Desire L,Drouin D,Pando M,Haun F.Etazolate improves performance in a foraging and homing task in aged rats.Eur J Pharmacol.2010;634(1−3):95−100.PMID 20223232.
10.Li LX,Cheng YF,Lin HB,Wang C,Xu JP.Zhang HT.Prevention of cerebral ischemia−induced memory deficits by inhibitation of phosphodiesterase−4 in rats.Metab Brain Dis.2011;26(1):37−47.PMID 21327879.
11.Gallant M,Aspiotis R,Day S,et al.Discovery of MK−0952,a selective PDE4 inhibitor for the treatment of long−term memory loss and mild cognitive impairment.Bioorg Med Chem Lett.2010;20(22):6387−93.PMID 20933411.
12.Heaslip RJ,Evans DY.Emetic,central nervous system,and pulmonary activities of rolipram in the dog.Eur J Phamacol.1995;286(3):281−90.PMID 8608790.
13.Bruno O,Fedele E,Prickaerts J,et al.GEBR−7b,a novel PDE4D selective inhibitor that improves memory in rodents at non−emetic doses.Br J Pharmacol.2011;164(8):2054−63.PMID 21649644.
14.Mackenzie SJ,Houslay MD.Action of rolipram on specific PDE4 cAMP phosphosiesterase isoforms and on the phosphorylation of cAMP−response−element−binding protein(CREB) and p38 mitogen−activated protein(MAP) kinase in U937 monocytic cells.Biochem J.2000;347(Pt2):571−8.10749688.
15.Xu W,Kasper LH,Lerach S,Jeevan T,Brindle PK.Individual CREB−target genes dictate usage of distinct cAMP−respnsive coactivation mechanisms.EMBO J.2007;26(12):2890−903.PMID 17525731.
16.Benito E,Valor LM,Jimenez−minchan M,Huber W,Barco A.cAMP response element−binding protein is a primary hub of activity−driven neuronal gene expression.J Neurosci.2011;31(50):18237−50.PMID 22171029.
17.Lee J,Kim CH,Simon DK,et al.Mitochondrial cyclic AMP response element−binding protein(CREB) mediates mitochondrial gene expression and neuronal survival.J Biol Chem.2005;280(49):40398−401.PMID 16207717.
18.Desseroth K,Bito H,Tsien RW.Signaling form synapse to nucleus:postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity.Neuron.1996;16(1):89−101.PMID 8562094.
19.Kida S.A Functional Role for CREB as a Positive Regulator of Memory Formation and LTP.Exp Neurobiol.2012;21(4):136−40.PMID 23319873.
20.Suzuki A,Fukushima H,Mukawa T,et al.Upregulation of CREB−mediated transcription enhances both short− and long−term memory.J Neurosci.2011;31(24):8786−802.PMID 21677163.
21.Ammon HP,Mueller AB.Forskolin:from an ayurvedic remedy to a modern agent.Planta Med.1985;51(6):473−7.PMID 17345261.
22.Seamon KB,Daly JW.Forskolin:a unique diterpene activator of cyclic AMP−generating systems.J Cyclic Nucleotide Res.1981;7(4):201−24.PMID 6278005.
23.Barad M,Bourtchouladze R,Winder DG,Golan H,Kandel E.Rolipram,a type IV−specific phosphodiesterase inhibitor,facilitates the establishment of long−lasting long−term potentiation and inproves memory.Proc Natl Acad Sci USA.1998;95(25):15020−5.PMID 9844008.
24.Brown JE,Rice−evans CA.Luteolin−rich artichoke extract protects low density lipoprotein from oxidation in vitro.Free Radic Res.1998;29(3):247−55.PMID 9802556.
25.Yu MC,Chen JH,Lai CY,Han CY,Ko WC.Luteolin,a non−selective competitive inhibitor of phosphodiesterases 1−5,displaced [3H]−rolipram from high−affinity rolipram binding sites and reversed xylazine/ketamine−induced anesthesia.Eur J Pharmacol.2010;627(1−3):269−75.PMID 19853596.
26.Kitagawa Y,Hirano T,Kawaguchi SY.Prediction and validation of a mechanism to control the threshold for inhibitory synaptic plasticity.Mol Syst Biol.2009;5:280.PMID 19536203.
27.Puzzo D,Sapienza S,Arancio O,Palmeri A.Role of phosphodiesterase 5 in synaptic plasticity and memory.Neuropsychiatr Dis Treat.2008;4(2):371−87.PMID 18728748.
28.Otmakhov N,Khibnik L,Otmakhova N,et al.Forskolin−induced LTP in the CA1 hippocampal region is NMDA receptor dependent.J Neurophysiol.2004;91(5):1955−62.PMID 14702333.
29.Piech−dumas KM,Tank AW.CREB mediates the cAMP−responsiveness of the tyrosine hydroxylase gene:use of an antisense RNA strategy to produce CREB−deficient PC12 cell lines.Brain Res Mol Brain Res.1999;70(2):219−30.PMID 10407170.
30.Kumer SC,Vrana KE.Intricate regulation of tyrosine hydroxylase activity and gene expression.J Neurochem.1996;67(2):443−62.PMID 8764568.
31.Slominski A,Zmijewski MA,Pawelek J.L−tyrosine and L−dihydroxyphenylalanine as hormone−like regulators of melanocyte functions.Pigment Cell Melanoma Res.2012;25(1):14−27.PMID 21834848.
32.Amadasi A,Betroldi M,Contestabile R,et al.Pyridoxal 5’−phosphate enzymes as targets for therapeutic agents.Curr Med Chem.2007;14(12):1291−324.PMID 17504214.
33.Curtin BF,Pal N,Gordon RK,Nambiar MP.Forkolin,an inducer of cAMP,up−regulates acethylcholinesterase expression and protects against organophosphate exposure in neuro 2A cells.Mol Cell Biochem.2006;290(1−2):23−32.PMID 16924422.
34.Hartvig P,Lindstroem B,Pettersson E,Wiklund L.Reversal of postoperative somnolence using a two−rate infusion of physostigmine.Acta Anaesthesiol Scand.1989;33(8):681−5.PMID 2589000.
35.White HL,Scates PW.Acetyl−L−carnitine as a precursor of acetylcholine.Neutochem Res.1990;15(6):597−601.PMID 2215852.
36.Alasbahi RH,Melzig MF.(2012)“Forskolin and derivatives as tools for studying the role of cAMP.”Phamazie.2012 Jan;67(1):5−13.PMID 22393824.
37.Yu MC,Chen JH,Lai CY,Han Cy,Ko WC.(2010)“Luteolin,a non−selective competitive inhibitor of phosphodiesterase 1−5,displaced[3H]−rolipram from high−affinity rolipram binding sites and reversed xylazine/ketamine−induced anesthesia.”Eur JPhamacol.2010 Feb 10;627(1−3):269−75.doi:10.1016/j.ejphar.2009.10.031.Epub 2009 Oct 22 PMID:19853596.
38.Harvey AL,Young LC,Viljoen AM,Gericke NP.(2011)“Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids.”J Ethnopharmacol.2011 Oct 11;137(3):1124 9.doi:10.1016/j.jep.2011.07.035.Epub 2011 Jul 20.PMID:21798331.
39.Dwight E.Matthews(2008)“An Overview of Phenylalanine and Tyrosine Kinetics in Human”J Nutr.Author manuscript;available in PMC 2008 March 17.Published in final edited form as:J Nutr.2007 June;137(6 Suppi 1):1549S−1575S.PMCID:PMC2268015.
40.Lichtstein HC,Gunsalus IC,Umbreit WW(1945).“Function of vitamin B6 group;pyridoxal phospshate(codecarboxylase)in transamination”(PDF).J Bioi Chem.161(1):311−20.PMID 21005738.
41.Rani PJ,Panneerselvam C.(2011).“Protective efficacy of L−carinitine on acetylchokinesterase activity in aged rat brain.”J Gerontal A Bioi Sci Med Sci.2001 Mar;56(3):B140−1.PMID:11253151.
42.Villa RF,Ferrari F.Gorini A.(2013)“ATP−ases fo synaptic plasma menbranes in striatum:Enzymatic systems for synapses functionality by in vivo administration of 1−acetylcarnitine in relation to Parkinson’s Disease.”Neuroscience.2013 Jun 25;248C:414−426.doi:10.1016/j.neuroscience.2013.06.027.[Epub ahead of print]PMID:23806723
43.Curtin BF,Pal N,Gordon RK,Nambiar MP.(2006).“Forskolin,an inducer of cAMP,upregulates acetylcholineesterase expression and protects against organophosphete exposure in neuro 2A cells”Mol Cell Biochem.2006 Oct;290(1−2):23−32.Epub 2006 Aug 19.PMID 16924422.
44.Gong B,Vitolo OV,Trinchese F,Liu S,Shelanski M,Arancio 0.,(2004)“Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.”J Clin Invest.2004 Dec;114(11):1624−34.PMID:15578094.
45.Voisin P,Bernard N.(2013)“Cyclic AMP−dependent regulation of tyrosine hydoroxylase mRNA and immunofluorescence levels in rat retinal precursor cells.”Cell Tissue Res.2013 May;352(2):207−16.doi:10.1007/s00441−013−1555−4.Epub 2013 Jan 26.PMID:2335501.
46.Chan AL,Huang HL,Chien HC,Chen CM,Lin CN,Ko WC.Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high−affinity[(3)H]−rolipram binding in guinea pig tissues.Invest New Drugs.2008;26(5):417−24.PMID 18264679.
47.Yang YL,Hsu HT,Wang KH,Wang CS,Chen CM,Ko WC.Hesperidin−3’−o−methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin−induced airway hyperresponsiveness.Evid Based Complement Alternat Med.2012;2012:908562.PMID 23082087.
48.Park SJ,Ahmad F,Philp A,et al.Resveratol ameliorates aging−related metabolic phenotypes by inhibiting cAMP phosphodiesterases.Cell.2012;148(3):421−33.PMID 22304913.
49.Ko WC,Lin LH,Shen HY,Lai CY,Chen CM,Shih CH.Biochanin a,a phytoestrogenic isoflavone with selective inhibitation of phosphodiesterase 4,suppresses ovalbumin−induced airway hyperresponsiveness.Evid Based Complement Alternat Med.2011;2011:635058.PMID 21437195.
50.Nichols MR,Morimoto BH.Tyrosine kinase−independent inhibitation of cyclic−AMP phosphodiesterase by genistein and tyrphostin 51.Arch Biochem Biophys.1999;366(2):224−30.PMID 10356287.
51.Harvey AL,Young LC,Vijoen AM,Gericke NP.Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids.J Ethnopharmacol.2011;137(3):1124−9.PMID 21798331.
52.Shoba G,Joy D,Joseph T,Majeed M,Rajendran R,Srinivas PS.Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.Planta Med.1998;64(4):353−6.PMID 9619120.
53.Johnson JJ,Nihal M,Siddiqui 1A,et al.Enhancing the bioavailability of resveratrol by combining it with piperine.Mol Nutr Food Res.2011;55(8):1169−76.PMID 21714124.
Claims (58)
- 有効量のフォスフォジエステラーゼ4(PDE4)阻害剤と、環状アデノシン一リン酸(cAMP)増加剤とを含む、
被験者の認知機能を増すための向知性作用を有する組み合わせ剤。 - 有効量のアセチル−L−カルニチンまたはその生理学的に許容できる塩をさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記PDE4阻害剤は、フラボノイド、アルカロイド、若しくは、スチルベノイド、または、それらの組み合わせを含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記PDE4阻害剤は、ルテオリン、ケルセチン、ヘスペリジン、バイオカニンA、ゲニステイン、メセンブレノン、若しくは、レスベラトロール、若しくは、それらのグリコシド、それらの生理学的に許容できる塩、または、それらの組み合わせを含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記cAMP増加剤は、ラブダンジテルペンである、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記cAMP増加剤は、フォルスコリン、そのグリコシド、またはその生理学的に許容できる塩である、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記cAMP増加剤は、フォルスコリンであり、
該フォルスコリンは、前記組み合わせ剤の一日用量あたり、約0.9mg〜約4.4mgの範囲で含まれる、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のアセチル−L−カルニチンをさらに含み、
前記cAMP増加剤はフォルスコリンであり、
フォルスコリンに対するアセチル−L−カルニチンの質量比は、約200:1である、
請求項1に記載の向知性薬作用を有する組み合わせ剤。 - L−フェニルアラニン、L−カルニチン、アセチル−L−カルニチン、ビタミンB6、ピペリン、およびそれらの生理学的に許容できる塩からなる群から選ばれる成分の1つ、または該群から選ばれる成分の組み合わせを有効量含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のアセチル−L−カルニチンをさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のピペリンをさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のL−フェニルアラニンをさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のビタミンB6をさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記PDE4阻害剤、前記cAMP増加剤、またはその両方は、1または複数の植物抽出物の形態で、前記組み合わせ剤中に存在する、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 有効量のアセチル−L−カルニチンをさらに含み、
前記PDE4阻害剤は、ルテオリン、ケルセチン、ヘスペリジン、バイオカニンA、ゲニステイン、メセンブレノン、若しくは、レスベラトロール、若しくは、それらのグリコシド、それらの生理学的に許容できる塩、または、それらの組み合わせであり、
前記cAMP増加剤は、フォルスコリン、そのグリコシド、またはその生理学的に許容できる塩であり、
前記組み合わせ剤は、L−フェニルアラニン、L−カルニチン、アセチル−L−カルニチン、ビタミンB6、ピペリン、およびそれらの生理学的に許容できる塩からなる群から選ばれる成分の一つ、または該群から選ばれる成分の組み合わせをさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 栄養補給剤の形態であり、
前記cAMP増加剤として、フォルスコリン、およびアセチル−L−カルニチンを有効量含み、有効量のPDE4阻害剤を含む植物抽出物をさらに含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - フォルスコリンに対するアセチル−L−カルニチンの質量比は、約200:1である、
請求項16に記載の向知性作用を有する組み合わせ剤。 - 前記補給剤の一日用量あたり、前記フォルスコリンが約0.9mg〜約4.4mgの範囲で存在する、
請求項16に記載の向知性作用を有する組み合わせ剤。 - 前記フォルスコリンは、コレウスフォルスコリ抽出物の形態で前記栄養補給剤中に存在する、
請求項16に記載の向知性作用を有する組み合わせ剤。 - 前記PDE4阻害剤は、フラボノイド、アルカロイド、若しくはスチルベノイド、またはそれらの組み合わせを含む、
請求項16に記載の向知性作用を有する組み合わせ剤。 - 前記PDE4阻害剤は、ルテオリン、ケルセチン、ヘスペリジン、バイオカニンA、ゲニステイン、メセンブレノン、若しくは、レスベラトロール、若しくは、それらのグリコシド、それらの生理学的に許容できる塩、または、それらの組み合わせである、
請求項16に記載の向知性作用を有する組み合わせ剤。 - 前記フォルスコリンは、コレウスフォルスコリの形態で、前記栄養補給剤中に存在し、フォルスコリンに対するアセチル−L−カルニチンの質量比は、約200:1である、
請求項21に記載の向知性作用を有する組み合わせ剤。 - 栄養補給剤の形態であり、
前記PDE4阻害剤として、フォスフォジエステラーゼ4(PDE4)阻害フラボノイドと、前記cAMP増加剤として、環状アデノシン一リン酸(cAMP)増加ラブダンジテルペンと、アセチル−L−カルニチンとを有効量含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記フラボノイドはルテオリンである、
請求項23に記載の向知性作用を有する組み合わせ剤。 - 前記栄養補給剤は、フラボノイド源としてのアーティチョーク抽出物を含む、
請求項23に記載の向知性作用を有する組み合わせ剤。 - 前記ラブダンジテルペンは、フォルスコリンである、
請求項23に記載の向知性作用を有する組み合わせ剤。 - L−フェニルアラニン、L−カルニチン、ビタミンB6、およびピペリンからなる群から選ばれる成分の一つ、または該群から選ばれる任意の組み合わせを、さらに有効量含む、
請求項23に記載の向知性作用を有する組み合わせ剤。 - 有効量のピペリンをさらに含む、
請求項23に記載の向知性作用を有する組み合わせ剤。 - 有効量のL−フェニルアラニンをさらに含む、
請求項23に記載の向知性薬作用を有する組み合わせ剤。 - 有効量のビタミンB6をさらに含む、
請求項23に記載の向知性作用を有する組み合わせ剤。 - 栄養補給剤の形態であり、一日用量の形態において、
前記PDE4阻害剤源として、5%シナリンに規格化された、約202.5mg〜約990mgのアーティチョーク抽出物と、
前記cAMP増加剤として、約0.9mg〜約4.4mgのフォルスコリンと、
約180mg〜約880mgのアセチル−L−カルニチンと、を含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 前記栄養補給剤の一日用量あたり、約112.5mg〜約550mgのL−フェニルアラニン、前記栄養補給剤の一日用量あたり、約2.25mg〜約11mgのビタミンB6、および前記栄養補給剤の一日用量あたり、約10mg〜約20mgのピペリンからなる群から選ばれる成分の一つ、または該群から選ばれる成分の任意の組み合わせをさらに含む、
請求項31に記載の向知性作用を有する組み合わせ剤。 - フォルスコリンに対するアセチル−L―カルニチンの質量比は、約200:1である、
請求項31に記載の向知性作用を有する組み合わせ剤。 - 前記栄養補給剤の一日用量あたり、
約112.5mg〜約550mgのL−フェニルアラニンと、
前記栄養補給剤の一日用量あたり、約2.25mg〜約11mgのビタミンB6とをさらに含む、
請求項31に記載の向知性作用を有する組み合わせ剤。 - カプセルの形態であり、カプセルあたりに、
前記PDE4阻害剤源として、5%シナリンに規格化された、約300mgのアーティチョーク抽出物と、
前記cAMP増加剤として、約4/3mgのフォルスコリンと、
約250mgのアセチル−L−カルニチンと、
約500/3mgのL−フェニルアラニンと、
約5/3mgのビタミンB6とを含む、
請求項1に記載の向知性作用を有する組み合わせ剤。 - 認知機能を増すことを必要とする被験者の認知機能を増す方法であって、
環状アデノシン一リン酸(cAMP)増加剤およびアセチル−L−カルニチンを有効量含み、かつ有効量のPDE4阻害剤を含む植物抽出物をさらに含む栄養補給剤を、前記被験者に投与することを含む、方法。 - 前記cAMP増加剤はフォルスコリン、そのグリコシド、またはその生理学的に許容できる塩である、
請求項36に記載の方法。 - 前記PDE4阻害剤は、フラボノイド、アルカロイド、若しくはスチルベノイド、またはそれらの組み合わせを含む、
請求項36に記載の方法。 - 前記PDE4阻害剤は、ルテオリン、ケルセチン、ヘスペリジン、バイオカニンA、ゲニステイン、メセンブレノン、若しくは、レスベラトロール、若しくは、それらのグリコシド、それらの生理学的に許容できる塩、または、それらの組み合わせを含む、
請求項36に記載の方法。 - 前記cAMP増加剤はフォルスコリンである、
請求項39に記載の方法。 - フォルスコリンに対するアセチル−L−カルニチンの質量比は、約200:1である、
請求項40に記載の方法。 - 前記フォルスコリンは、コレウスフォルスコリ抽出物の形態で、前記栄養補給剤中に存在する、
請求項40に記載の方法。 - 前記PDE4阻害剤はフラボノイドであり、前記環状cAMP増加剤はラブダンジテルペンである、
請求項36に記載の方法。 - 前記フラボノイドはルテオリンである、
請求項43に記載の方法。 - 前記栄養補給剤は、前記フラボノイド源として、アーティチョーク抽出物を含む、
請求項43に記載の方法。 - 前記ジテルペンはフォルスコリンである、
請求項45に記載の方法。 - 前記栄養補給剤は、L−フェニルアラニン、L−カルニチン、ビタミンB6、およびピペリンからなる群から選ばれる成分の一つ、または該群から選ばれる成分の任意の組み合わせを、治療上有効量さらに含む、
請求項45に記載の方法。 - 前記栄養補給剤は、有効量のピペリンをさらに含む、
請求項45に記載の方法。 - 前記栄養補給剤は、有効量のL−フェニルアラニンをさらに含む、
請求項45に記載の栄養補給剤。 - 前記栄養補給剤は、有効量のビタミンB6をさらに含む、
請求項45に記載の栄養補給剤。 - 前記栄養補給剤は、一日用量の形態において、
前記PDE4阻害剤として、5%シナリンに規格化された、約202.5mg〜約990mgのアーティチョーク抽出物と、
前記cAMP増加剤として、約0.9mg〜約4.4mgのフォルスコリンと、
約180mg〜約880mgのアセチル−L−カルニチンとを含む、
請求項36に記載の方法。 - 前記栄養補給剤は、前記栄養補給剤の一日用量あたり、約112.5mg〜約550mgのL−フェニルアラニン、前記栄養補給剤の一日用量あたり、約2.25mg〜約11mgのビタミンB6、および前記栄養補給剤の一日用量あたり、約10mg〜約20mgのピペリンからなる群から選ばれる成分の一つ、または該群から選ばれる成分の組み合わせをさらに含む、
請求項51に記載の方法。 - フォルスコリンに対するアセチル−L−カルニチンの質量比は、約200:1である、
請求項51に記載の方法。 - 前記栄養補給剤は、
前記栄養補給剤の一日用量あたり、約112.5mg〜約550mgのL−フェニルアラニンと、
前記栄養補給剤の一日用量あたり、約2.25mg〜約11mgのビタミンB6と、をさらに含む、
請求項51に記載の方法。 - 前記被験者は、一日用量あたり、前記栄養補給剤の2または3カプセルを投与され、
各カプセルは、
前記PDE4阻害剤源として、5%シナリンに規格化された、約300mgのアーティチョーク抽出物と、
前記cAMP増加剤として、約4/3mgのフォルスコリンと、
約250mgのアセチル−L−カルニチンと、
約500/3mgのL−フェニルアラニンと、
約5/3mgのビタミンB6とを含む、
請求項36に記載の方法。 - メセンブレノンと、環状アデノシン一リン酸(cAMP)増加ラブダンジテルペンと、を有効量含む、
栄養補給剤。 - 前記栄養補給剤は、前記メセンブレノン源として、カンナ抽出物を含む、
請求項56に記載の栄養補給剤。 - 認知機能を増すことを必要とする被験者の認知機能を増す方法であって、
前記被験者に、請求項56に記載の栄養補給剤を投与することを含む、
方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361883433P | 2013-09-27 | 2013-09-27 | |
US61/883,433 | 2013-09-27 | ||
US201462046953P | 2014-09-06 | 2014-09-06 | |
US62/046,953 | 2014-09-06 | ||
US201462047055P | 2014-09-07 | 2014-09-07 | |
US62/047,055 | 2014-09-07 | ||
PCT/US2014/057923 WO2015048590A1 (en) | 2013-09-27 | 2014-09-27 | Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016538328A true JP2016538328A (ja) | 2016-12-08 |
JP2016538328A5 JP2016538328A5 (ja) | 2018-09-13 |
Family
ID=52740399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016545257A Pending JP2016538328A (ja) | 2013-09-27 | 2014-09-27 | Pde4阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 |
Country Status (7)
Country | Link |
---|---|
US (4) | US9149457B2 (ja) |
EP (1) | EP3049101A4 (ja) |
JP (1) | JP2016538328A (ja) |
AU (2) | AU2014324608B2 (ja) |
CA (1) | CA2925318C (ja) |
IL (1) | IL244743B (ja) |
WO (1) | WO2015048590A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014324608B2 (en) | 2013-09-27 | 2019-08-08 | Justin SHER | Nutraceutical compositon for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation |
EP3621617A1 (en) * | 2017-05-12 | 2020-03-18 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
US10758505B2 (en) | 2017-12-01 | 2020-09-01 | Innovus Pharmaceuticals, Inc. | Therapeutic compositions and methods |
US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
US10864205B2 (en) | 2017-12-01 | 2020-12-15 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for improving sexual health in men and women |
US10500199B2 (en) | 2017-12-01 | 2019-12-10 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for increasing cognitive functions |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
IT202000006094A1 (it) * | 2020-03-23 | 2021-09-23 | A M Italy S R L | Composizione per l’uso nella terapia, in particolare per la cura dell’alzheimer |
US11999694B2 (en) | 2021-10-29 | 2024-06-04 | Sensorium Therapeutics, Inc. | Delivery of therapeutic alkaloid compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925377A (en) * | 1997-08-07 | 1999-07-20 | Nova Pharmaceutical Co. | Dietary supplement composition |
WO2000062812A1 (en) * | 1999-04-20 | 2000-10-26 | Advocare International Llc | Nutritional composition for improved cognitive performance |
US20060171938A1 (en) * | 2005-02-03 | 2006-08-03 | Stock Jeffry B | Compositions and methods for enhancing cognitive function |
US20110064720A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
US20130034530A1 (en) * | 2011-04-29 | 2013-02-07 | David R. Fantz | Dietary Supplement Cognitive Support System |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
NZ543486A (en) * | 2005-11-10 | 2009-03-31 | Fonterra Corporate Res And Dev | Compositions of CIS-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof |
US8501581B2 (en) | 2006-03-29 | 2013-08-06 | Micron Technology, Inc. | Methods of forming semiconductor constructions |
WO2007123699A1 (en) * | 2006-03-30 | 2007-11-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for modulating melanogenesis by using a mclr agonist |
US20080044390A1 (en) | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
WO2008153426A1 (en) * | 2007-06-15 | 2008-12-18 | Sealord Group Limited | Anti-inflammatory composition and use thereof |
US8029830B2 (en) * | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
WO2009143391A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
EP2408446B1 (en) | 2009-03-20 | 2019-09-11 | HG&H Pharmaceuticals (Pty) Limited | Use of pharmaceutical compositions containing mesembrenone |
CN102573496B (zh) * | 2009-07-01 | 2015-08-26 | 玛格塞蒂克斯公司 | 缓释镁组合物及其用途 |
FR2948566B1 (fr) | 2009-07-30 | 2012-08-10 | Expanscience Lab | Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
AU2014324608B2 (en) | 2013-09-27 | 2019-08-08 | Justin SHER | Nutraceutical compositon for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation |
-
2014
- 2014-09-27 AU AU2014324608A patent/AU2014324608B2/en active Active
- 2014-09-27 JP JP2016545257A patent/JP2016538328A/ja active Pending
- 2014-09-27 CA CA2925318A patent/CA2925318C/en active Active
- 2014-09-27 WO PCT/US2014/057923 patent/WO2015048590A1/en active Application Filing
- 2014-09-27 EP EP14847980.1A patent/EP3049101A4/en not_active Withdrawn
- 2014-09-27 US US14/499,143 patent/US9149457B2/en active Active
-
2016
- 2016-03-23 IL IL244743A patent/IL244743B/en active IP Right Grant
- 2016-03-25 US US15/081,787 patent/US10058529B2/en active Active
-
2019
- 2019-02-21 US US16/281,793 patent/US20190274996A1/en not_active Abandoned
- 2019-08-21 AU AU2019219780A patent/AU2019219780A1/en not_active Abandoned
-
2020
- 2020-01-06 US US16/735,424 patent/US20200147033A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925377A (en) * | 1997-08-07 | 1999-07-20 | Nova Pharmaceutical Co. | Dietary supplement composition |
WO2000062812A1 (en) * | 1999-04-20 | 2000-10-26 | Advocare International Llc | Nutritional composition for improved cognitive performance |
US20060171938A1 (en) * | 2005-02-03 | 2006-08-03 | Stock Jeffry B | Compositions and methods for enhancing cognitive function |
US20110064720A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
US20130034530A1 (en) * | 2011-04-29 | 2013-02-07 | David R. Fantz | Dietary Supplement Cognitive Support System |
Non-Patent Citations (3)
Title |
---|
BRAIN RESEARCH, vol. Vol.405,No.2, JPN6018016032, 1987, pages p371−374 * |
NEUROPSYCHOPHARMACOLOGY, vol. [online], JPN6018016033, 1 August 2013 (2013-08-01), pages 2013 - 183 * |
脂質栄養学, vol. Vol.19,No.1, JPN6018016031, 2010, pages p19−23 * |
Also Published As
Publication number | Publication date |
---|---|
EP3049101A4 (en) | 2018-01-10 |
CA2925318A1 (en) | 2015-04-02 |
IL244743B (en) | 2020-11-30 |
CA2925318C (en) | 2021-01-19 |
US20190274996A1 (en) | 2019-09-12 |
US10058529B2 (en) | 2018-08-28 |
EP3049101A1 (en) | 2016-08-03 |
WO2015048590A1 (en) | 2015-04-02 |
US20160213642A1 (en) | 2016-07-28 |
AU2014324608B2 (en) | 2019-08-08 |
IL244743A0 (en) | 2016-04-21 |
AU2014324608A1 (en) | 2016-04-28 |
US9149457B2 (en) | 2015-10-06 |
AU2019219780A1 (en) | 2019-09-12 |
US20150093458A1 (en) | 2015-04-02 |
US20200147033A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200147033A1 (en) | Nutraceutical composition for pde4 inhibition, enhanced dopamine metabolism and long term potentiation | |
Wang et al. | Asiatic acid and maslinic acid attenuated kainic acid-induced seizure through decreasing hippocampal inflammatory and oxidative stress | |
Dajas et al. | Quercetin in brain diseases: Potential and limits | |
Chawla et al. | Radioprotective and antioxidant activity of fractionated extracts of berries of Hippophae rhamnoides | |
JP2008110996A (ja) | 体脂肪低減用組成物 | |
Angelone et al. | Distinct signalling mechanisms are involved in the dissimilar myocardial and coronary effects elicited by quercetin and myricetin, two red wine flavonols | |
Ku et al. | Garlic and its active metabolite allicin produce endothelium-and nitric oxide-dependent relaxation in rat pulmonary arteries. | |
da Rocha Lapa et al. | Vasorelaxant and hypotensive effects of the extract and the isolated flavonoid rutin obtained from Polygala paniculata L. | |
Ajagun‐Ogunleye et al. | Evaluation of the anti‐aging and antioxidant action of Ananas sativa and Moringa oleifera in a fruit fly model organism | |
US10500182B2 (en) | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache | |
Xu et al. | Sirtuins in macrophage immune metabolism: A novel target for cardiovascular disorders | |
US8840937B2 (en) | Composition and method for recovery from mild traumatic brain injury | |
CA2810793C (en) | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels | |
KR20150093141A (ko) | 생약재의 추출물을 유효성분으로 포함하는 뇌질환 또는 신경질환의 예방 또는 치료용 조성물 | |
JP4145659B2 (ja) | 細辛抽出物を含有する脳細胞保護及び記憶力増進用組成物 | |
López-Carreras et al. | Endothelium-dependent vascular relaxing effects of different citrus and olive extracts in aorta rings from spontaneously hypertensive rats | |
Shine et al. | Molecular interaction of naringin and its metabolite naringenin to human liver fibrosis proteins: An In Silico approach | |
Wang et al. | L-theanine as a promising agent on brain health-promoting foods–a review | |
US20130280354A1 (en) | Composition and Method for Using Sage | |
KR20150043867A (ko) | 생약재의 추출물을 유효성분으로 포함하는 뇌질환 또는 신경질환의 예방 또는 치료용 조성물 | |
US10105347B2 (en) | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels | |
US20080279968A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids | |
Luhata et al. | Natural products from Odontonema strictum promote neurite outgrowth in neuronal PC12 cells | |
US20220313675A1 (en) | Anti-Aging Telomere-Strengthening NAD+ Sirtuin Dietary Supplement Composition | |
KR20240073178A (ko) | 부채마 추출물 또는 디오신을 포함하는 기억력 개선, 신경염증 억제, 신경세포 사멸 억제, 또는 자가포식작용 촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180511 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180615 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180806 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190426 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20190517 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190531 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190607 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190712 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190719 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200327 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200403 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200619 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201016 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20201113 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20201113 |